Connect your AI

Sutro Biopharma STRO Tax on Share Settlement

Tax on Share Settlement at other companies

AnaptysBio, Inc.ANAB

$0-100%

Cogent Biosciences, Inc.COGT

$12.22M—

BridgeBio PharmaBBIO

$4.07M+129%

Theravance BiopharmaTBPH

$5.82M+566%

Other financials

Income statement

Revenue$14.5M-16.5%

Operating income-$29.7M+56.7%

Net income-$38.5M+49.3%

EPS (diluted)-$2.94+67.6%

Balance sheet

Cash & equivalents$73.7M-30.6%

Total debt$13.6M-36.3%

Total equity-$66.9M-159%

Total assets$242.0M-24.7%

Cash flow

Operating cash flow-$42.3M+37.7%

CapEx--100%

Free cash flow-$42.3M+37.8%

Valuation

Market cap$489.66M+624%

Enterprise value$429.61M-2,600%

P/S4.9×+3.9×

Profitability

Operating margin-120%-48.6pp

Net margin-154.2%-56.7pp

FCF margin-152.2%-51.1pp

Returns & leverage

Return on equity-234.2%—

Debt / equity0.5×+0.3×

Current ratio3.1×+1.0×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's tax on share settlement.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Sutro Biopharma's tax on share settlement?: Sutro Biopharma (STRO) reported tax on share settlement of $160K in Q1 2026.
How has Sutro Biopharma's tax on share settlement changed year-over-year?: Sutro Biopharma's tax on share settlement decreased by 11.1% year-over-year, from $180K to $160K.
What is the long-term trend for Sutro Biopharma's tax on share settlement?: Over 3 years (2022 to 2025), Sutro Biopharma's tax on share settlement has grown at a -10.5% compound annual growth rate (CAGR), from $463K to $332K.
What does tax on share settlement mean?: Cash paid to tax authorities for employee share vesting, where the company withholds shares and pays the tax obligation in cash.